Eli Lilly & Co. (LLY) Reports New Verzenio Phase 3 monarchE Trial Data Published in the Annals of Oncology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Eli Lilly (LLY) PT Lowered to $272 at Mizuho Securities
October 27, 2021 6:35 AM EDTMizuho Securities analyst Vamil Divan lowered the price target on Eli Lilly (NYSE: LLY) to $272.00 (from $279.00) while maintaining a Buy rating.
The analyst commented, "Lilly reported a mixed 3Q21, but focus remains on the future, with management announcing completion of its FDA submission... More
Too Early to Tell What Eli Lilly’s (LLY) Study Means for Biogen’s (BIIB) Aduhelm – Analyst
October 26, 2021 10:55 AM EDTEarlier today, as part of its Q321 Report, Eli Lilly and Company (NYSE: LLY) announced a rolling submission for donanemab in early Alzheimer's disease.
The company announces plans to conduct TRAILBLAZER-ALZ 4, a Phase 3 head-to-head clinical trial comparing donanemab to Biogens (NASDAQ:... More
Lilly kicks off application for Alzheimer's drug U.S. approval
October 26, 2021 6:31 AM EDTBy Manojna Maddipatla and Mrinalika Roy
(Reuters) -Eli Lilly said on Tuesday it has started the application process for a U.S. approval of its closely watched experimental Alzheimer's drug and expects a regulatory decision by the second half of 2022, potentially setting it up against rival Biogen's recently approved Aduhelm.
Lilly said it has started a real-time submission for its donanemab to the U.S. Food and Drug Administration for accelerated approval for use in early Alzheimer's disease.
Biogen used the same regulatory... More
Eli Lilly & Co. (LLY) Misses Q3 EPS by 2c
October 26, 2021 6:26 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.94, $0.02 worse than the analyst estimate of $1.96. Revenue for the quarter came in at $6.77 billion versus the consensus estimate of $6.6 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2021 EPS of $7.95-$8.05, versus the... More
